Veeda Clinical Unlisted Shares
821301Active
465
Loading chart data...
Key Indicators
Current Price
475
PAN Number
AACCC3633Q
ISIN Number
INE01HQ01026
Rs. 2992
P/E Ratio
8.5
P/B Ratio
2.82
Debt to Equity
0
ROE
-0.03
Book Value
168.67
Face Value
2
Total Shares
62999846
EPS
-0.06
Rating
Financial Annual Report Data Section
About Veeda Clinical Unlisted Shares
Founded in 2004 and headquartered in Ahmedabad, Veeda Clinical is a full-service independent CRO specializing in bioavailability/bioequivalence (BA/BE) studies, clinical trials, and regulatory support for global pharmaceutical clients. Veeda operates DCGI- and USFDA-approved facilities, making it a preferred partner for global generics and specialty pharma companies. The firm is backed by marquee investors like CX Partners, Somerset Indus Capital, and others. READ LESS ...
Financial Statement (Figures in cr)
P&L Statement
| P&L Statement |
|---|
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|
Frequently Asked Question
Veeda Clinical unlisted shares are equity shares of Veeda Clinical Research Ltd that are not currently traded on public exchanges. These shares are held privately and can be bought or sold through private deals before the IPO.
You can purchase Veeda shares through SEBI-registered intermediaries, private equity platforms, or directly from existing shareholders via negotiated transactions.
Risks include limited liquidity, lack of public financial disclosures, and uncertainty around IPO timelines. Pricing and valuations are subject to change based on company performance and market conditions.
Veeda filed DRHP in the past but delayed its IPO. Market reports and investor activity suggest a revival of IPO plans within the next 12–18 months, pending regulatory clearance.
Once Veeda is listed, your unlisted shares convert to listed equity, tradable on stock exchanges. This improves liquidity, transparency, and potentially offers capital gains on listing premium.
Top Unlisted Shares
Discover a range of services designed to meet your unique financial goals.